Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?

• 作者: Osamu Yokosuka Shingo Nakamoto Tatsuo Kanda
• 来源期刊: 世界病毒学杂志
• 学科: 医学
• 关键词: Hepatitis C virus Interleukin-28B INTERFERON Japan SUSTAINED VIROLOGIC response
• 年，卷（期）: 2015,（3）
• 页码范围: 178-184
• 页数: 7页
• 分类号: R

摘要

In 2009,several groups reported that interleukin-28B(IL28B)genotypes are associated with the response to peginterferon plus ribavirin therapy for chronic hepatitis C virus(HCV)infection in a genome-wide association study,although the mechanism of this association is not yet well understood.However,in recent years,tremendous progress has been made in the treatment of HCV infection.In Japan,some patients infected with HCV have the IL28B major genotype,which may indicate a favorable response to interferon-including regimens;however,certain patients within this group are also interferon-intolerant or ineligible.In Japan,interferonfree 24-wk regimens of asunaprevir and daclatasvir are now available for HCV genotype 1b-infected patients who are interferon-intolerant or ineligible or previous treatment null-responders.The treatment response to interferon-free regimens appears better,regardless of IL28B genotype.Maybe other interferon-free regimens will widely be available soon.In conclusion,although some HCV-infected individuals have IL28B favorable alleles,importance of IL28B will be reduced with availability of oral interferon free regimen.